journal
MENU ▼
Read by QxMD icon Read
search

Lung Cancer: Journal of the International Association for the Study of Lung Cancer

journal
https://www.readbyqxmd.com/read/29292070/corrigendum-to-cardiogenic-shock-in-a-patient-being-treated-with-atezolizumab-for-metastatic-non-small-cell-lung-cancer-lung-cancer-114-december-2017-106-107
#1
Ellen Liu, Avirup Guha, Kelly Jia, Andrew Morgan Ayers, Konstantinos Dean Boudoulas, Erin Bertino, Veronica Franco
No abstract text is available yet for this article.
December 29, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29289353/corrigendum-to-clinical-outcomes-of-black-vs-non-black-patients-with-locally-advanced-non-small-cell-lung-cancer-lung-cancer-114-december-2017-44-49
#2
Melissa A L Vyfhuis, Neha Bhooshan, Jason Molitoris, Søren M Bentzen, Josephine Feliciano, Martin Edelman, Whitney M Burrows, Elizabeth M Nichols, Mohan Suntharalingam, James Donahue, Marc Nagib, Shamus R Carr, Joseph Friedberg, Shahed Badiyan, Charles B Simone, Steven J Feigenberg, Pranshu Mohindra
No abstract text is available yet for this article.
December 27, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29254746/effectiveness-and-safety-of-nivolumab-in-advanced-non-small-cell-lung-cancer-the-real-life-data
#3
Elizabeth Dudnik, Mor Moskovitz, Sameh Daher, Sivan Shamai, Ekaterina Hanovich, Ahuva Grubstein, Tzippy Shochat, Mira Wollner, Jair Bar, Ofer Merimsky, Alona Zer, Daniel A Goldstein, Ariel Hammerman, Arnold Cyjon, Yelena Shechtman, Mahmood Abu-Amna, Dov Flex, Laila C Roisman, Nir Peled
OBJECTIVES: Nivolumab has recently received regulatory approval as a 2nd-line treatment of non-small cell lung cancer (NSCLC). The data regarding its effectiveness and safety in real life setting is lacking. MATERIALS AND METHODS: 260 consecutive patients with advanced NSCLC treated with nivolumab at five Israeli cancer centers between January 2015 and March 2016 were evaluated for overall survival (OS) and toxicity. OS was analyzed by the Cox proportional-hazards regression model...
November 23, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29179916/real-life-experience-with-nivolumab-for-the-treatment-of-non-small-cell-lung-carcinoma-data-from-the-expanded-access-program-and-routine-clinical-care-in-a-tertiary-cancer-centre-the-netherlands-cancer-institute
#4
Robert D Schouten, Mirte Muller, Cornedine J de Gooijer, Paul Baas, Michel van den Heuvel
No abstract text is available yet for this article.
November 17, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29174372/changing-health-care-costs-for-nsclc-what-does-it-mean
#5
EDITORIAL
Pieter E Postmus
No abstract text is available yet for this article.
November 11, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29146159/a-patient-with-malignant-pleural-mesothelioma-carrying-braf-v600e-mutation-responding-to-vemurafenib
#6
LETTER
Yao Chen, Baisong Chen, Xiaolian Zhu, Jianping Zhong
No abstract text is available yet for this article.
November 8, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29126573/lipoid-pneumonia-mimicking-multifocal-lung-cancer-in-a-patient-with-a-remote-laryngectomy-and-a-recently-diagnosed-lung-cancer-pet-ct-findings
#7
LETTER
Luis Gorospe, Raquel García-Latorre, Odile Ajuria-Illarramendi, Paola Arrieta, Rosa María Gómez-García, Gemma María Muñoz-Molina, María Eugenia Olmedo-García
No abstract text is available yet for this article.
November 7, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29126574/incidental-retroperitoneal-malignant-solitary-fibrous-tumor-detected-at-lung-cancer-screening-with-low-dose-thoracic-ct
#8
LETTER
Luis Gorospe, Joaquín Carlos Sánchez-Monforte, Jacobo Cabañas-Montero, Paola Arrieta, Vital Hevia-Palacios, María Eugenia Reguero-Callejas, Isabel García-Gómez-Muriel
No abstract text is available yet for this article.
November 6, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29096978/treatment-of-a-nsclc-patient-with-osimertinib-based-on-the-detection-of-the-egfr-t790m-resistance-mutation-in-cerebrospinal-fluid
#9
LETTER
Sandrine Théoleyre, Ingrid Masson, Guillaume Herbreteau, Audrey Vallée, Hélène Sénellart, Marc G Denis
No abstract text is available yet for this article.
October 28, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29290269/how-does-autoimmune-disease-impact-treatment-and-outcomes-among-patients-with-lung-cancer-a-national-seer-medicare-analysis
#10
Saad A Khan, Sandi L Pruitt, Lei Xuan, Una Makris, David E Gerber
BACKGROUND: The advent of cancer immunotherapy has made autoimmune disease in oncology populations clinically important. We analyzed the association of autoimmune disease with treatment and outcomes among lung cancer patients. METHODS: Using linked Surveillance Epidemiology and End Results (SEER)-Medicare data, we identified lung cancer patients diagnosed between 1992 and 2009 with autoimmune diseases. We recorded number and timing of autoimmune disease diagnoses, lung cancer treatment, and markers of healthcare utilization including emergency department visits, hospitalizations, and outpatient visits...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29290268/recurrence-dynamics-after-trimodality-therapy-neoadjuvant-concurrent-chemoradiotherapy-and-surgery-in-patients-with-stage-iiia-n2-lung-cancer
#11
Junghee Lee, Hong Kwan Kim, Byung Jo Park, Jong Ho Cho, Yong Soo Choi, Jae Ill Zo, Young Mog Shim, Hongryull Pyo, Yong Chan Ahn, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jhingook Kim
INTRODUCTION: We investigated the timing and patterns of recurrence after the treatment of stage IIIA (N2) non-small cell lung cancer via neoadjuvant concurrent chemoradiotherapy followed by surgery. MATERIALS AND METHODS: An institutional database was reviewed retrospectively between 1997 and 2013 (N=570). Eligible patients had pathologically proven N2 disease, and they completed the planned trimodality therapy with curative intent. The hazard rate function and competing risk analysis were used to evaluate the recurrence dynamics...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29290267/comparative-effectiveness-of-immune-checkpoint-inhibitors-for-previously-treated-advanced-non-small-cell-lung-cancer-a-systematic-review-and-network-meta-analysis-of-3024-participants
#12
Pui San Tan, Pedro Aguiar, Benjamin Haaland, Gilberto Lopes
INTRODUCTION: Role of PD-L1 expression to guide immunotherapies in previously treated advanced NSCLC remains unclear and there is a lack of data comparing immune checkpoint inhibitors (ICIs) with each other. This network meta-analysis (NMA) aims to compare survival with ICIs to docetaxel and perform indirect comparisons between ICIs in the PD-L1 unselected population and by PD-L1 expression levels. METHODS: PubMed was searched and study screening was performed by two independent reviewers...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29290266/long-term-outcomes-of-surgical-resection-for-stage-iv-non-small-cell-lung-cancer-a-national-analysis
#13
Chi-Fu Jeffrey Yang, Lin Gu, Shivani A Shah, Babatunde A Yerokun, Thomas A D'Amico, Matthew G Hartwig, Mark F Berry
OBJECTIVE: Treatment guidelines recommend surgical resection in select cases of stage IV non-small-cell lung cancer (NSCLC) but are based on limited evidence. This study evaluated outcomes associated with surgery in stage IV disease. METHODS: Factors associated with survival of stage IV NSCLC patients treated with surgery in the National Cancer Date Base (2004-2013) were evaluated using multivariable Cox proportional hazards analyses. Outcomes of the subset of patients with cT1-2, N0-1, M1 and cT3, N0, M1 disease treated with surgery or chemoradiation were evaluated using Kaplan-Meier analyses...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29290265/correlation-between-immune-related-adverse-events-and-efficacy-in-non-small-cell-lung-cancer-treated-with-nivolumab
#14
Koichi Sato, Hiroaki Akamatsu, Eriko Murakami, Seigo Sasaki, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Yasuhiro Koh, Hiroki Ueda, Masanori Nakanishi, Nobuyuki Yamamoto
OBJECTIVES: Patients treated with nivolumab often experience its unique adverse events, called immune-related adverse events (irAEs). Regarding the mechanisms of immune-checkpoint inhibitors (ICIs), the occurrence of irAEs may also reflect antitumor responses. Here, we report the clinical correlation between irAEs and efficacy in NSCLC patients treated with nivolumab. MATERIALS AND METHODS: Between December 2015 and February 2017, 38 advanced NSCLC patients were treated in our institution...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29290264/the-predictive-value-of-the-interferon-%C3%AE-release-assay-for-chemotherapy-responses-in-patients-with-advanced-non-small-cell-lung-cancer
#15
Hsu-Ching Huang, Wei-Juin Su, Chi-Lu Chiang, Jia-Yih Feng, Hsin-Yi Huang, Ching-Hsiung Lin, Sheng-Hao Lin, Ching-Yuan Cheng, Chao-Hua Chiu
OBJECTIVES: IFN-γ takes part in immunologic responses to cancer and its interactions with chemotherapy have also been described. Our previous study had showed an association between phytohemagglutinin (PHA)-stimulated IFN-γ (PSIG) response and overall survival in patients with advanced non-small-cell lung cancer (NSCLC). Here, we aimed to evaluate the correlation between PSIG and chemotherapy responses. MATERIALS AND METHODS: From January 2011 to August 2012, 340 newly diagnosed patients with lung cancer were enrolled in a prospective latent tuberculosis observational study...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29290263/abundant-tumor-promoting-stromal-cells-in-lung-adenocarcinoma-with-hypoxic-regions
#16
Hiroshi Nakamura, Tomohiro Ichikawa, Shoko Nakasone, Tomohiro Miyoshi, Masato Sugano, Motohiro Kojima, Satoshi Fujii, Atsushi Ochiai, Takeshi Kuwata, Keiju Aokage, Kenji Suzuki, Masahiro Tsuboi, Genichiro Ishii
OBJECTIVES: Carbonic anhydrase IX (CAIX) is a marker of hypoxia and its expression by cancer associated fibroblasts (CAFs) was reportedly associated with the poor prognosis of lung adenocarcinoma. This study aimed to characterize the hypoxic microenvironment containing CAIX (+) CAFs. MATERIALS AND METHODS: First, we evaluated the clinicopathological significance of CAIX expression by CAFs in 3cm and above lung adenocarcinoma (n=188). We then compared the expressions of E-cadherin, ezrin, ALDH-1, CD44, EGFR, HSF-1, Glut-1, and PD-L1 in cancer cells, as well as those of CD204 and podoplanin in stromal cells between CAIX (+) CAFs and CAIX (-) CAFs cases (n=25, each)...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29290262/gcc2-alk-as-a-targetable-fusion-in-lung-adenocarcinoma-and-its-enduring-clinical-responses-to-alk-inhibitors
#17
Junhong Jiang, Xue Wu, Xiaoling Tong, Wangzhi Wei, Anan Chen, Xiaonan Wang, Yang W Shao, Jianan Huang
OBJECTIVES: ALK, RET and ROS1 fusions have been identified as treatable targets in 5%-15% of non-small-cell lung cancers, and thanks to the advanced sequencing technologies, their new partner genes have been steadily detected. Here we identified a rare fusion of ALK (GCC2-ALK) in a patient with advanced lung adenocarcinoma and monitored the treatment efficacy of ALK inhibitors on this patient. We further performed in vitro functional studies of this fusion protein for evaluating its oncogenic potential...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29290261/does-nivolumab-for-progressed-metastatic-lung-cancer-fulfill-its-promises-an-efficacy-and-safety-analysis-in-20-general-hospitals
#18
Kurt G Tournoy, Michiel Thomeer, Paul Germonpré, Sofie Derijcke, Rebecca De Pauw, Daniëlla Galdermans, Karl Govaert, Elke Govaerts, Rob Schildermans, Isabelle Declercq, Nele De Brucker, Karin Pat, Rika Van Herreweghe, Luc Van Zandweghe, Luc Vanmaele, Valerie Van Damme, Heidi Marien, Sofie De Craene, Isabelle Fabry, Patrick Alexander, Piet Vercauter, Ingel Demedts
OBJECTIVES: In patients with refractory or recurrent non-small-cell lung cancer (NSCLC) after first line chemotherapy, phase III trials showed superiority of nivolumab, an IgG4 programmed death-1 immune-checkpoint-inhibitor antibody, over docetaxel. We evaluated case mix, effectiveness and safety of nivolumab upon implementation in general practice. MATERIALS AND METHODS: In 20 general hospitals, all consecutive NSCLC patients treated with nivolumab within the medical need program (inclusion period 12 months) in Flanders - Belgium were evaluated...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29290260/high-expression-of-topoisomerase-ii-predicts-favorable-clinical-outcomes-in-patients-with-relapsed-small-cell-lung-cancers-receiving-amrubicin
#19
Yosuke Miura, Kyoichi Kaira, Reiko Sakurai, Noriaki Sunaga, Ryusei Saito, Takeshi Hisada, Masanobu Yamada
OBJECTIVES: Amrubicin monotherapy is a treatment option for patients with relapsed small cell lung cancers (SCLCs). Topoisomerase-II (Topo-II) - a target of amrubicin - has been reported as a predictive or prognostic marker for chemosensitivity or outcomes in patients with various malignancies. Here, we investigated the prognostic role of Topo-II expression in patients with relapsed SCLCs who underwent amrubicin monotherapy. MATERIALS AND METHODS: Eighty-three patients with relapsed SCLCs who received amrubicin monotherapy between 2004 and 2015, after progression beyond first-line chemotherapy, were enrolled in the study...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29290259/radiomics-and-radiogenomics-in-lung-cancer-a-review-for-the-clinician
#20
REVIEW
Rajat Thawani, Michael McLane, Niha Beig, Soumya Ghose, Prateek Prasanna, Vamsidhar Velcheti, Anant Madabhushi
Lung cancer is responsible for a large proportion of cancer-related deaths across the globe, with delayed detection being perhaps the most significant factor for its high mortality rate. Though the National Lung Screening Trial argues for screening of certain at-risk populations, the practical implementation of these screening efforts has not yet been successful and remains in high demand. Radiomics refers to the computerized extraction of data from radiologic images, and provides unique potential for making lung cancer screening more rapid and accurate using machine learning algorithms...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"